The Australian patent represents the first patent granted for the Company's new point-of-care testing platform

 Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,  announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*.

Initially filed in May 2022 before being granted in June of this year, the patent is the first granted for the new platform and provides broad protection in Australia for the Company's proprietary system and methods used for nucleic acid detection and analysis. The claims specifically cover the design and operation of the Co-Dx PCR Pro™ instrument and test cups, including its approach to performing high-quality polymerase chain reaction (PCR) testing outside of traditional laboratory environments.

"This patent represents another significant milestone in securing global protection for our technology as we continue expanding the potential applications of the point-of-care PCR platform," said Dwight Egan, CEO of Co-Dx. "From the beginning, Co-Dx's goal has been to make accurate, accessible PCR testing available where it is needed most, and strengthening our global IP portfolio is essential to that mission."

The patent grant in Australia also provides strategic protection in a region where Co-Dx and potential commercial partners may choose to introduce or distribute the Co-Dx PCR platform in the future. Australia recently experienced a record-breaking flu season, and securing patent coverage in the market serves as a key defensive measure to protect the commercial potential of the platform, including the Co-Dx PCR Flu A/B, COVID, RSV multiplex test (currently in clinical performance testing).

Co-Diagnostics' Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments. The platform leverages the Company's patented Co-Primers® technology and is intended to enable rapid, sensitive, and specific molecular diagnostics across a broad range of infectious disease applications.